|
To listen to individual tracks now, click the  icon. To download tracks to a CD, right-click the icon for your preferred file type. Files are provided in WMA for users with Windows Media Player or  MP3 for users with other audio players.
|
| Track 1 |
Introduction by Neil Love, MD |
|
|
| Track 2 |
Perspectives on the 2005 ASCO meeting |
|
|
| Track 3 |
Evolution of clinical research with bevacizumab in breast cancer |
|
|
| Track 4 |
Potential predictors of response to bevacizumab |
|
|
| Track 5 |
ECOG-E2100: Paclitaxel with or without bevacizumab as first-line therapy for metastatic breast cancer |
|
|
| Track 6 |
Bevacizumab-associated side effects |
|
|
| Track 7 |
Progression-free and overall survival observed in E2100 |
|
|
| Track 8 |
Clinical implications of E2100 trial results |
|
|
| Track 9 |
Bevacizumab in the second- and third-line settings |
|
|
| Track 10 |
Bevacizumab dosing |
|
|
| Track 11 |
Nonprotocol use of bevacizumab/capecitabine |
|
|
| Track 12 |
Future clinical trials with bevacizumab in the adjuvant setting |
|
|
| Track 13 |
Clinical implications of adjuvant trastuzumab trial results |
|
|
| Track 14 |
Rates of distant recurrence observed in the combined NCCTG-N9831/NSABP-B-31 analysis |
|
|
| Track 15 |
Potential benefit of concurrent versus sequential chemotherapy/trastuzumab |
|
|
| Track 16 |
Adjuvant trastuzumab for patients with node-negative, HER2-positive disease |
|
|
| Track 17 |
Quality control for HER2 testing |
|
|
| Track 18 |
Cardiovascular events in carboplatin/docetaxel/trastuzumab arm of BCIRG 006 |
|
|
| Track 19 |
Time course for initiating treatment with adjuvant trastuzumab |
|
|
| Track 20 |
Perspectives on the cost of newer treatments |
|
|
| Track 21 |
Cardiac monitoring of patients on adjuvant trastuzumab |
|
|
| Track 22 |
Personal perspective: A new age of breast cancer management |
|
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
Results from combined NCCTG-N9831/NSABP-B-31 analysis |
|
|
| Track 3 |
Concurrent versus sequential trastuzumab/chemotherapy in the adjuvant setting |
|
|
| Track 4 |
Potential predictors of trastuzumab-related cardiac toxicity |
|
|
| Track 5 |
Rationale for including anthracycline-based chemotherapy in NSABP-B-31 |
|
|
| Track 6 |
Strategies to monitor cardiac function in patients receiving adjuvant trastuzumab |
|
|
| Track 7 |
Discontinuation of adjuvant trastuzumab in patients with decreases in cardiac ejection fraction |
|
|
| Track 8 |
Counseling patients about the risks and benefits of adjuvant trastuzumab |
|
|
| Track 9 |
Adjuvant trastuzumab for patients with node-negative disease |
|
|
| Track 10 |
Duration and time course of adjuvant therapy with trastuzumab |
|
|
| Track 11 |
Future directions in clinical research with trastuzumab |
|
|
| Track 12 |
Case discussion: Woman with 25 positive lymph nodes treated on NSABP-B-31 |
|
|
| Track 13 |
Quality control with HER2 testing in community practice |
|
|
| |
|
|
|
 |
Jack Cuzick, PhD
John Snow Professor of Epidemiology
Cancer Research UK Centre for Epidemiology, Mathematics and Statistics
Wolfson Institute of Preventive Medicine
Barts and the London, Queen Mary’s School of Medicine and Dentistry
London, United Kingdom
Click here to download the entire interview |
|
|
|
| Track 1 |
Introduction by Dr Love |
|
|
| Track 2 |
68-month follow-up data from the ATAC trial |
|
|
| Track 3 |
Increased incidence of hysterectomy with tamoxifen versus anastrozole in ATAC |
|
|
| Track 4 |
Rates of bone loss and bone fractures in ATAC |
|
|
| Track 5 |
Rationale for increased benefit of anastrozole in patients with ER-positive, PR-negative phenotype |
|
|
| Track 6 |
Reduction in early recurrences with anastrozole |
|
|
| Track 7 |
Potential benefit of anastrozole versus tamoxifen in ER-positive, HER2-positive disease |
|
|
| Track 8 |
Switching to an aromatase inhibitor after two to three years of tamoxifen |
|
|
| Track 9 |
Time course and biologic rationale for breast cancer recurrence |
|
|
| Track 10 |
Importance of examining optimal duration of adjuvant aromatase inhibitors |
|
|
| Track 11 |
Design, background and initial results from BIG 1-98 |
|
|
| Track 12 |
Cardiac effects of tamoxifen |
|
|
| Track 13 |
Risk of cardiovascular disease and aromatase inhibitors |
|
|
| Track 14 |
Anastrozole as a potential chemopreventative agent |
|
|
| Track 15 |
Prevention of contralateral tumors in clinical trials of adjuvant aromatase inhibitors |
|
|
| Track 16 |
Potential antitumor effect of adjuvant bisphosphonates |
|
|
| Track 17 |
Arthralgias and changes in cognitive function associated with aromatase inhibitors |
|
|
| Track 18 |
Concordance between estrogen receptor status in primary and secondary breast cancers |
|
|
| Track 19 |
COX-2 inhibitors and aspirin as potential chemopreventative agents |
|
|
|
|
